BioXcel Therapeutics says it does not expect to file delayed quarterly report or future periodic reports
BTAI•BioXcel Therapeutics does not expect to file its delayed quarterly report for the period ended September 30, 2026, or any subsequent periodic reports. It cited limited staff and resources during bankruptcy proceedings and the winding down of operations.
1. Reports not expected
BioXcel Therapeutics, now BX Liquidation, said it will miss the filing extension for its quarterly report for the period ended September 30, 2026, and does not expect to file that report or any subsequent periodic reports. The company said limited staff and resources devoted to bankruptcy proceedings and winding down operations prevent completion of its financial statements and the auditor’s review.
2. Bankruptcy and asset sale
The company filed for Chapter 11 bankruptcy on August 27, 2026, and sold substantially all its assets on October 26, 2026. Its executive officers, including the chief financial officer, were removed from office effective October 31, 2026.




